Company Description
Evaxion A/S, a clinical-stage biotech company, develops artificial intelligence-powered immunology vaccines.
The company develops EVX-01, which is in phase 2 global multi-center clinical trial for the treatment of advanced melanoma; EVX-03, DNA-based cancer vaccine for the treatment of solid tumors; and EVX-04, a therapeutic cancer vaccine candidate, which is in phase 1 trial for acute myeloid leukemia.
Its programs also include vaccines that are in pre-clinical stage, which includes EVX-B1, a multi-component prophylactic vaccine targeting skin and soft tissue infections with S.
aureus bacteria; EVX-B2 to target multi-component prophylactic vaccine against gonorrhea bacteria; EVX-B3 to target bacterial pathogen associated with repeated infections; and EVX-V1, a multi-component prophylactic vaccine candidate for cytomegalovirus.
The company was formerly known as Evaxion Biotech A/S and changed its name to Evaxion A/S in May 2025.
Evaxion A/S was incorporated in 2008 and is based in Horsholm, Denmark.
| Country | Denmark |
| Founded | 2008 |
| IPO Date | Feb 5, 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 46 |
| CEO | Helen Tayton-Martin |
Contact Details
Address: Dr. Neergaards Vej, 5th Floor Horsholm, 2970 Denmark | |
| Phone | 45 53 53 18 50 |
| Website | evaxion.ai |
Stock Details
| Ticker Symbol | EVAX |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $10.00 |
| CIK Code | 1828253 |
| CUSIP Number | 29970R303 |
| ISIN Number | US29970R3030 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Helen Katrina Tayton-Martin MBA, Ph.D. | Chief Executive Officer |
| Andreas Holm Mattsson M.Sc. | Founder and Chief AI Officer |
| Thomas Frederik Schmidt M.Sc. | Chief Financial Officer |
| Dr. Birgitte Rono Ph.D. | Chief Scientific Officer |
| Benjamin Ole Wolthers | Vice President of Clinical Development |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 30, 2026 | 6-K | Report of foreign issuer |
| Mar 19, 2026 | 6-K | Report of foreign issuer |
| Mar 19, 2026 | 6-K | Report of foreign issuer |
| Mar 18, 2026 | 3 | Initial statement of beneficial ownership of securities |
| Mar 18, 2026 | 3 | Initial statement of beneficial ownership of securities |
| Mar 18, 2026 | 3 | Initial statement of beneficial ownership of securities |
| Mar 18, 2026 | 3 | Initial statement of beneficial ownership of securities |
| Mar 18, 2026 | 3 | Initial statement of beneficial ownership of securities |
| Mar 18, 2026 | 3 | Initial statement of beneficial ownership of securities |
| Mar 18, 2026 | 3 | Initial statement of beneficial ownership of securities |